Page results
-
People with the acquired communication disorder aphasia – which involves problems with the understanding or production of speech –have benefitted greatly from a two-year programme of therapy at the National Hospital for Neurology and Neurosurgery at UCLH.
-
This page explains what patient-initiated follow-up (PIFU) involves after your treatment for endometrial (uterine or womb) cancer.
-
UCLH will play a vital role in a new respiratory virus study.
-
Christmas is an exciting time even if it will be a bit different for us all this year. We might be spending more time inside, making us less active than usual for this time of year. However, it is still a good time to relax and enjoy some Christmas treats.
-
UCLH is the first NHS trust to pilot a personalised educational package for patients living with stroke.
-
CAMLIS is the Royal London Hospital for Integrated Medicine (RLHIM) Complementary and Alternative Medicine Information and Library Service and is situated on the ground floor of the hospital.
-
The Clinical Research Facility at UCLH has been awarded £10 million in funding to deliver cutting edge early phase health research in areas including cancer and dementia.
-
The NHS has become the first healthcare system in the world to provide a new blood group genotyping test which is set to transform care for patients living with sickle cell disorder and thalassaemia.
-
Our staff have rated UCLH as the top trust in England, improving on our ranking from last year when we were third best in England and top in London.
-
Information about the Therapeutic Plasma Exchange at NHNN for patients, carers, and families.
File results
-
FOI/2023/0294 - Patient entertainment
-
FOI/2023/0295 - Strikes and Trust use of the BMA rate card
-
FOI/2023/0296 - Consultant workforce information
-
FOI/2023/0300 - Post-mortem examinations for 2019, 2020, 2021 and 2022
-
FOI/2023/0301 - Meat served at the Trust that may contain nitrates or nitrites
-
FOI/2023/0303 - Sexual harassment from patients towards staff in 2022
-
FOI/2023/0304 - Chronic lymphocytic leukaemia treatments
-
FOI/2023/0308 - Treatment for biologic and biosimilar products within rheumatology
-
FOI/2023/0310 - Biologic treatment/ medicines in dermatology
-
FOI/2023/0313 - Consent, confidentiality and information sharing in mental healthcare and suicide